Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 4, 2018
Context: The filing discloses the submission of investor presentation materials intended for use at the LDMicro 8th Invitational in Bel Air, California, held from June 4-6, 2018. The company is designated as an emerging growth company.
Key Financial Metrics
This filing does not contain financial statements, revenue figures, profit data, cash flow metrics, debt levels, or liquidity ratios. The document serves solely to disclose the existence and content of a slide presentation attached as Exhibit 99.1.
Material Changes
No material changes to financial performance or operations are reported in this specific filing. The document references a presentation that speaks as of the date of the report but explicitly disclaims any obligation to update the materials for future events.
Guidance, Outlook, and Risks
- Management Commentary: The company intends to post the presentation materials on its Investor Relations website (www.processapharma.com).
- Legal Disclaimer: The information contained in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
- Outlook: No specific forward-looking guidance or numerical targets are provided within the text of this 8-K.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Investor Presentation dated June 4, 2018) for specific business updates, as the 8-K text only references the attachment.
- Verify the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Check the company's website for the posted presentation materials to access the detailed content referenced in this filing.